BrightEdge — 2026 Investments

2 investments dated 2026 · listed companies and verified rows first · show all

CellCentriccellcentric.com in 𝕏Late Stage · May 2026 · $220M

CellCentric develops inobrodib, a small-molecule oral p300/CBP inhibitor intended to treat multiple myeloma and other cancers.

BiotechHealthtechMedical Devices

Azim Surani(Co-founder)

Co-investorsAvego BioScience Capital Future Planet Capital HBM Healthcare Investments HBM Partners RA Capital Sofinnova Partners +3 more

TippingPoint Biosciencestippingpointbiosciences.com inSeed · Mar 2026 · $4.5M

TippingPoint Biosciences is a therapeutics company developing a drug discovery platform that targets unstructured regions in chromatin proteins to treat diseases caused by dysfunctional genome chromatin packaging, with a focus on cancer.

BiotechDeep TechHealthtechSan Francisco, US

Laura Hsieh(Founder & CEO)in

Co-investorsFREEFLOW SOSV Empath Ventures Sazze StoryHouse XEIA Venture Partners

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.